Beijing Konruns Pharmaceutical Co Ltd (SHG:603590) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Konruns Pharmaceutical Co Ltd (603590)
Beijing Konruns Pharmaceutical Co Ltd (SHG:603590) has a market capitalization of $823.70 Million (CN¥5.63 Billion) as of May 2, 2026. Listed on the SHG stock exchange, this China-based company holds position #10007 globally and #2847 in its home market, demonstrating a -5.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Konruns Pharmaceutical Co Ltd's stock price CN¥35.40 by its total outstanding shares 159010477 (159.01 Million). Analyse Beijing Konruns Pharmaceutical Co Ltd (603590) cash conversion ratio to see how efficiently the company converts income to cash.
Beijing Konruns Pharmaceutical Co Ltd Market Cap History: 2018 to 2026
Beijing Konruns Pharmaceutical Co Ltd's market capitalization history from 2018 to 2026. Data shows growth from $707.85 Million to $823.70 Million (0.83% CAGR).
Beijing Konruns Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Konruns Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.66x
Beijing Konruns Pharmaceutical Co Ltd's market cap is 0.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.96x
Beijing Konruns Pharmaceutical Co Ltd's market cap is 12.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $707.85 Million | $973.16 Million | $263.93 Million | 0.73x | 2.68x |
| 2019 | $780.16 Million | $1.07 Billion | $266.08 Million | 0.73x | 2.93x |
| 2020 | $837.87 Million | $808.64 Million | $183.36 Million | 1.04x | 4.57x |
| 2021 | $743.22 Million | $809.78 Million | $147.99 Million | 0.92x | 5.02x |
| 2022 | $576.82 Million | $866.73 Million | $101.49 Million | 0.67x | 5.68x |
| 2023 | $886.05 Million | $920.01 Million | $150.45 Million | 0.96x | 5.89x |
| 2024 | $547.27 Million | $825.40 Million | $42.22 Million | 0.66x | 12.96x |
Competitor Companies of 603590 by Market Capitalization
Companies near Beijing Konruns Pharmaceutical Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Beijing Konruns Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Beijing Konruns Pharmaceutical Co Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Beijing Konruns Pharmaceutical Co Ltd's market cap moved from $707.85 Million to $ 823.70 Million, with a yearly change of 0.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥823.70 Million | -10.94% |
| 2025 | CN¥924.91 Million | +69.01% |
| 2024 | CN¥547.27 Million | -38.24% |
| 2023 | CN¥886.05 Million | +53.61% |
| 2022 | CN¥576.82 Million | -22.39% |
| 2021 | CN¥743.22 Million | -11.30% |
| 2020 | CN¥837.87 Million | +7.40% |
| 2019 | CN¥780.16 Million | +10.21% |
| 2018 | CN¥707.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Beijing Konruns Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $823.70 Million USD |
| MoneyControl | $823.70 Million USD |
| MarketWatch | $823.70 Million USD |
| marketcap.company | $823.70 Million USD |
| Reuters | $823.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more